Effect of Nigella sativa oil in patients with polycystic ovary

Phase 3

Recruiting

• Conditions: Polycystic ovary syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20231124060163N1
• Lead Sponsor: Ardabil University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Oligomenorrhea or lack of ovlation
polycystic ovaries based on ultrasound
Androgenic hormone changes in laboratory or clinical form (the presence of hirsutism)

Exclusion Criteria

Type 2 diabets
Thyroid disease
Adernal hyperplasia
Autoimmune disease
Hyperprolactinemia
People with structured physical activity or scheduled exercise
If three months before entering the study,they use a special diet or special drugs that may affect the results ,they will be excluded from the study ,such as anti-obesity drugs,induction ovulation,antidepressants,insulin sensivity,oral contraceotives,asprin,and anti-prostaglandin drugs
If there are signs of pregnancy,they will be excludedfrom the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Malondialdehyde(MDA). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.;Total antioxidant capacity(TAOC). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.

Secondary Outcome Measures

Name	Time	Method
Triglyceride. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.;Cholesterol. Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.;High-density lipoprotein (HDL). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.;Low-density lipoprotein (LDL). Timepoint: Before and after 12 weeks of intervention. Method of measurement: Determination of serum level.